Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 391 to 400 of 858 total matches.

In Brief: Adderall

   
The Medical Letter on Drugs and Therapeutics • Mar 28, 2005  (Issue 1205)
, M.D., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle ...
On February 9, 2005, Health Canada suspended the marketing of Adderall XR (Shire), a mixture of amphetamine salts used to treat attention-deficit hyperactivity disorder (ADHD) (Med Lett Drugs Ther 1994; 36:109). The immediate-release form of Adderall was never marketed in Canada. The withdrawal was based on 20 reports internationally of sudden death in patients taking the drug. These deaths, 14 of them in children, were not linked to overdose or abuse. The FDA decided that the number of sudden deaths was no greater than expected among the large number of people taking the drug, but because 5...
Med Lett Drugs Ther. 2005 Mar 28;47(1205):28 |  Show IntroductionHide Introduction

In Brief: Hypo- and Hyperglycemia with Gatifloxacin (Tequin)

   
The Medical Letter on Drugs and Therapeutics • Mar 13, 2006  (Issue 1230)
., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D ...
A study now available on the web site of The New England Journal of Medicine (LY Park-Wyllie et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. www.nejm.org, published online March 1, 2006) reports an increased risk of hypoglycemia (RR 4.3) and hyperglycemia (RR 16.7) with use of gatifloxacin (Tequin), a fluoroquinolone antibiotic. The Medical Letter published an article on this risk in 2003 (vol. 45, page 64); at that time the extent to which other fluoroquinolones carried the same risk was unclear. The recent report indicates that, except for a slightly increased...
Med Lett Drugs Ther. 2006 Mar 13;48(1230):24 |  Show IntroductionHide Introduction

In Brief: Telithromycin Hepatotoxicity

   
The Medical Letter on Drugs and Therapeutics • Apr 24, 2006  (Issue 1233)
, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University ...
Telithromycin (Ketek) is an oral erythromycin derivative FDA-approved for treatment of mild to moderate community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial sinusitis (Med Lett Drugs Ther 2004; 46:66). It is generally considered an alternative antibiotic because of its cost, potential for adverse effects including visual disturbances, exacerbation of myasthenia gravis, hepatotoxicity and drug interactions. A recent report (Ann Intern Med 2006; 144:415) described serious hepatotoxicity probably related to telithromycin in three patients, including one who died...
Med Lett Drugs Ther. 2006 Apr 24;48(1233):33 |  Show IntroductionHide Introduction

Correction: Panitumumab Dosage

   
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007  (Issue 1262)
., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
In the CLINICAL STUDIES - Other Cancers paragraph (Med Lett Drugs Ther 2007; 49:35), the dosage in the first line should be 2.5 mg/kg, not 25 mg/kg.
Med Lett Drugs Ther. 2007 Jun 4;49(1262):48 |  Show IntroductionHide Introduction

Interleukin-2

   
The Medical Letter on Drugs and Therapeutics • Sep 07, 1990  (Issue 826)
al, J Clin Oncol, 7:486, 1989; F Laghi Pasini et al, Lancet, 1:674, 1989; JP Dutcher et al, J Clin ...
Recombinant interleukin-2 (IL-2; Proleukin - Cetus), a lymphokine that stimulates growth of T lymphocytes, is available from the National Cancer Institute on an investigational basis for treatment of renal cell carcinoma and malignant melanoma. Although recently released in many European countries, the drug has not been approved for marketing by the US Food and Drug Administration.
Med Lett Drugs Ther. 1990 Sep 7;32(826):85-6 |  Show IntroductionHide Introduction

Alpha-Galactosidase to Prevent Gas

   
The Medical Letter on Drugs and Therapeutics • Apr 02, 1993  (Issue 893)
to the first bite of the offending food after cooling; food temperatures higher than 130° F may inactivate ...
The enzyme alpha-galactosidase (Beano - AkPharma), derived from a mold and classified as a food, is sold without presecription in pharmacies and food stores. The manufacturer recommends taking the anzyme to decrease intestinal gas producted by eating the high-fiber diets now widely recommended in the USA.
Med Lett Drugs Ther. 1993 Apr 2;35(893):29-30 |  Show IntroductionHide Introduction

Dolasetron for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

   
The Medical Letter on Drugs and Therapeutics • May 08, 1998  (Issue 1026)
antagonists (F Roila et al, Eur J Cancer, 33:1364, 1997). A randomized trial in 609 patients receiving ...
Dolasetron (Anzemet - Hoechst Marion Roussel), a selective serotonin (5-HT3) receptor antagonist similar to ondansetron (Zofran) and granisetron (Kytril - Medical Letter, 36:61, 1994) is now available for both oral and intravenous use in prevention of nausea and vomiting due to cancer chemotherapy. A 5-HT3 antagonist plus dexamethasone (Decadron, and others) is the most effective regimen for prevention of acute vomiting caused by cancer chemotherapy. Dolasetron has also been approved by the FDA for prevention and treatment of postoperative nausea and...
Med Lett Drugs Ther. 1998 May 8;40(1026):53-4 |  Show IntroductionHide Introduction

The Atkins Diet

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2000  (Issue 1080)
Meinertz, M.D., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F ...
Nearly 30 years after the first publication of Dr. Atkins' Diet Revolution promoting a high-protein, extremely low-carbohydrate diet, patients once again are asking their physicians about the Atkins diet.
Med Lett Drugs Ther. 2000 Jun 12;42(1080):52 |  Show IntroductionHide Introduction

Docosanol Cream (Abreva) for Recurrent Herpes Labialis

   
The Medical Letter on Drugs and Therapeutics • Nov 13, 2000  (Issue 1092)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew Maurer, M.D ...
Doconsanol 10% cream, a long-chain saturated alcohol, has been approved by the FDA for over-the-counter treatment of herpes labialis.
Med Lett Drugs Ther. 2000 Nov 13;42(1092):108 |  Show IntroductionHide Introduction

Once-a-week Alendronate (Fosamax)

   
The Medical Letter on Drugs and Therapeutics • Mar 19, 2001  (Issue 1100)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew ...
Once-a-week formulations of alendronate (Fosamax) in 35- and 70-mg tablets have now been approved by the FDA and are being heavily promoted for prevention and treatment of postmenopausal osteoporosis. A new formulation of risedronate (Actonel) for once-a-week use is under development and may be available next year.
Med Lett Drugs Ther. 2001 Mar 19;43(1100):26 |  Show IntroductionHide Introduction